Background
==========

Osteomyelitis (OM) is one of the most challenging bone infections, characterized by inflammatory destruction of bone marrow and surrounding bone, caused by an infecting microorganism \[[@b1-amjcaserep-20-482],[@b2-amjcaserep-20-482]\]. Its incidence is low, since the normal bone is highly resistant to infection, and most cases occur in patients with risk factors such as diabetes, immunosuppression, malignancy, decubitus ulcers, surgery, trauma, chronic intravenous drug users, and/or smoking \[[@b3-amjcaserep-20-482]\]. Despite the low incidence of OM, the number of cases have increased over the last decades, partly due to a significant increase in the prevalence of patients at risk \[[@b4-amjcaserep-20-482]\].

The prognosis of OM depends on the immune status and comorbidities of the patient, and on the virulence of the infecting microorganism \[[@b5-amjcaserep-20-482]\]. Gram-negative bacilli such as *Klebsiella pneumoniae* represent a minor portion of all the microorganisms isolated in OM \[[@b6-amjcaserep-20-482]\]. However, with the global emergence of nosocomial infections by highly drug-resistant CPKp, we expect an increasing incidence of OM caused by this agent, particularly among immunocompromised patients \[[@b7-amjcaserep-20-482],[@b8-amjcaserep-20-482]\]. So far, only 2 cases of OM by CPKp have been reported \[[@b9-amjcaserep-20-482],[@b10-amjcaserep-20-482]\]. Patients with hematologic malignancies and stem cell transplant recipients are a very high-risk population for both severe OM and CPKp infections \[[@b11-amjcaserep-20-482]\].

The pathophysiology of OM is multifactorial, and the microorganism may reach the bone by either hematogenous spread or spread from a contiguous focus \[[@b1-amjcaserep-20-482],[@b12-amjcaserep-20-482]\]. In adults, OM cases result mostly from a contiguous focus of infection with vascular insufficiency, as observed in diabetic patients. OM from a contiguous focus without vascular insufficiency occurs most frequently after trauma or surgery \[[@b13-amjcaserep-20-482]--[@b15-amjcaserep-20-482]\]. Hematogenous OM is primarily a disease of children but may also occur in adults, particularly in those at risk for blood stream infection, such as immunocompromised patients, patients with in-dwelling catheters, and intravenous drug users \[[@b13-amjcaserep-20-482],[@b14-amjcaserep-20-482]\].

According to disease duration, OM can be classified as acute or chronic \[[@b1-amjcaserep-20-482]\]. Acute OM corresponds to the initial phase of bone infection, and may present with fever, raised levels of inflammatory markers, and in the hematogenous form, with positive blood cultures (BCs). Following untreated infection or treatment failure, OM may progress to a chronic phase, which is characterized by the persistence of the microorganism, and the presence of necrotic bone (sequestrum) and fistulous tracts \[[@b16-amjcaserep-20-482]\]. Chronic OM may present as a recurrent or intermittent disease, with periods of quiescence of variable duration.

The successful management of OM requires timely and prolonged administration of pathogen-directed antibiotic treatment. This can be a serious challenge, particularly in immunocompromised patients, in which resistance can develop rapidly upon therapy, leading to treatment failure. In these cases, extensive surgical debridement is required, in addition to antibiotics \[[@b18-amjcaserep-20-482]--[@b21-amjcaserep-20-482]\].

We present these 2 cases to illustrate 2 different clinical presentations of OM by CPKp, and to raise awareness of this severe diagnosis, particularly among patients with hematologic malignancies and stem cell transplant recipients.

Case Report
===========

Case 1
------

A 49-year-old white female was admitted to our department with the diagnosis of acute lymphoblastic leukemia, and was treated with a first course of induction chemotherapy with high-dose cyclophosphamide, vincristine, doxorubicin, and dexamethasone. Three weeks later, she developed painless neutropenic enterocolitis, and after BC sampling we started empiric antibacterial therapy with meropenem (1 gr q8h) and amikacin (1gr q24h). Multidrug-resistant CPKp *(Kp1),* as defined by Magiorakos et al. \[[@b22-amjcaserep-20-482]\], was isolated after 48 h of incubation. Bacteria isolated on cultures (*Kp*) and their susceptibility patterns are listed in [Table 1](#t1-amjcaserep-20-482){ref-type="table"}. Susceptibility to each antibiotic was defined according to the observed minimum inhibitory concentration (MIC), which were interpreted using the 2017 European Committee Antimicrobial Susceptibility Testing (EUCAST) recommendations and breakpoint tables. Based on these results, we added colistin to the antibiotic regimen (a loading dose of 8 MU IV, followed by a maintenance dose of 4 MU IV q12h), with no clinical improvement. BCs repeated after 48 h remained positive for CPKp*,* which now displayed a higher meropenem MIC *(Kp2)*, and we decided to increase the meropenem dose to 2 gr q8h, in a 3-h extended infusion. Despite treatment, the patient's condition deteriorated, with clinical instability and substantial increase in the C-reactive protein (CRP) level (36.9 mg/dL) and leukocyte count (23 599 cells ×10^9^/L). She was admitted to the intensive care unit (ICU), where she rapidly progressed to multi-organ failure, requiring invasive mechanical ventilation and renal replacement therapy. BCs collected at ICU admission isolated a CPKp with increased amikacin MIC *(Kp3),* and amikacin was suspended. An abdominal/pelvic computed tomography (CT) scan was performed to evaluate the abdomen, and incidentally found intramedullary gas bubbles in the iliac bone and in the right femoral neck and head, suggestive of OM ([Figure 1](#f1-amjcaserep-20-482){ref-type="fig"}). Repeated BCs were positive for CPKp fully resistant to amikacin *(Kp4).* We admitted treatment failure, and decided to increase the dose of colistin (5 MU IV q12h) and associated tigecycline (200 mg loading dose, followed by 100 mg q12h), despite an unknown tigecycline susceptibility pattern.

To confirm the diagnosis of OM and re-evaluate disease status, we performed a bone biopsy and bone marrow aspiration from the posterior iliac crest. The aspirate morphology showed disease remission, with no blasts, and the bone culture was positive for CPKp with a pandrug-resistant pattern *(Kp5).* Her condition worsened over the following days and she died of exacerbation of multi-organ failure.

Case 2
======

A 47-year-old black female was admitted to our department with the diagnosis of aplastic anemia. Here, she received an initial immunosuppressive regimen with cyclosporine, anti-thymocyte globulin, and methylprednisolone. During treatment, she developed neutropenic fever with bacteriemia due to CPKp *(Kp1).* Bacteria isolated on cultures (*Kp*) and their susceptibility patterns are listed in [Table 2](#t2-amjcaserep-20-482){ref-type="table"}. A 14-day course of colistin (a loading dose of 8 MU, followed by a maintenance dose of 4 MU q12h) and amikacin (1 gr q24h) was completed with successful clinical response. Ten months later, she underwent an allogeneic hematopoietic stem cell transplant from a related donor. At the time of neutrophil engraftment, she developed a painful abscess in the right thigh, 5 cm in diameter, and its content was drained by aspiration. Due to clinical stability and absence of fever, we collected blood samples and postponed antibacterial therapy until culture results were available. After 48 h of incubation, cultures of the drained abscess fluid yielded CPKp susceptible only to colistin, tigecycline, and fosfomycin *(Kp2);* BCs were negative*.* We then initiated dual therapy with colistin (8 MU loading dose, followed by 4 MU q12h) and tigecycline (200 mg loading dose, followed by 100 mg q12). Despite treatment, the patient became febrile; the inflammatory lesion increased in size, and CRP level increased to a maximum of 31 mg/dL. Several BC sets were collected, with negative results. A CT scan of the thigh was performed, showing a deep collection adjacent to the femur, suggestive of OM ([Figure 2A, 2B](#f2-amjcaserep-20-482){ref-type="fig"}). This image was confirmed by magnetic resonance imaging (MRI), which showed an intraosseous abscess 14 cm in length. This abscess was connected to a subcutaneous collection measuring 5.6 cm in diameter, via an opening in the femoral metaphyseal region ([Figure 2C](#f2-amjcaserep-20-482){ref-type="fig"}). The patient underwent extensive surgical debridement of the right femur, followed by the same regimen of IV antibiotics for 6 weeks, with improvement of clinical condition. The endomedular culture grew a CPKp (Kp3) with a similar susceptibility pattern as the previous isolate. At the end of treatment, a whole-body bone scintigraphy with gadolinium showed inflammatory activity in the right femur, suggestive of OM. However, the patient was asymptomatic, with complete healing of the surgical wound and negative CRP, and she was discharged home without further antibacterial therapy. She currently presents no pain in the right leg, and is in complete hematologic recovery while still under post-transplant cyclosporine-based immunosuppression.

Discussion
==========

The spread of CPKp, members of the Enterobacteriaceae family, is an emerging public health threat. Carbapenemases can confer resistance or reduced susceptibility to various groups of antibiotics, which limits treatment options and results in significantly increased mortality \[[@b8-amjcaserep-20-482]\].

Despite being frequently encountered in nosocomial infections, CPKp are uncommon pathogens causing OM, with very few cases described in the literature.

Patients with hematologic malignancies and stem cell transplant recipients are at risk for OM and CPKp infections due to the severe immunosuppression caused by prolonged neutropenia, lymphocyte dysfunction (humoral and cell-mediated), chemo-therapy-induced gastrointestinal mucositis, prolonged hospitalization, and the use of broad-spectrum antibacterial agents \[[@b8-amjcaserep-20-482]\].

The nonspecific signs and symptoms of OM may lead to a delay in diagnosis, which, in the context of immunosuppression and infection with a resistant microorganism, can result in an unfavorable outcome.

These 2 cases are clear examples of the effect of host factors, bacterial virulence, and time to diagnosis and treatment on the outcome of OM. Although both cases were immunosup-pressed patients, in Case 1 the patient developed a prolonged neutropenia, followed by a severe gastrointestinal mucositis and multi-organ failure. In contrast, in Case 2 the patient had a rapid neutrophil recovery after stem cell transplant and remained clinically stable throughout follow-up. Comparing the bacterial virulence, in Case 1 there were 5 consecutive isolates of CPKp, with a progressively reduced susceptibility to antibiotics. The initial isolate *Kp1* was a multi-drug-resistant bacterium only susceptible to aminoglycosides (except for gentamicin), polymyxins, and carbapenems. Isolates *Kp2* to *Kp4* had an increase in the MICs, initially for both carbapenems and subsequently for amikacin; these were extensively drug-resistant bacteria \[[@b22-amjcaserep-20-482]\]. *Kp5*, isolated in the bone, was fully resistant to all the antibiotics, and thus was considered a pan-drug-resistant bacterium \[[@b11-amjcaserep-20-482],[@b22-amjcaserep-20-482]\]. In this case, we observed a persistent and sustained bacteremia by extensively drug-resistant CPKp, and the bone culture was positive for a pandrug-resistant CPKp. However, in Case 2 there was no bacteremia, and the endomedular culture was positive for extensively drug-resistant CPKp. We assume that the emergence of colistin and amikacin resistance, in Case 1 and Case 2, respectively, were related to strain evolution caused by drug-selection pressure and antibiotic overuse.

Regarding the clinical presentation, in Case 1 there were only nonspecific signs and symptoms of neutropenic sepsis, with no local inflammation, and the late diagnosis was based on an incidental radiological finding, confirmed with a positive bacterial bone culture. In contrast, in Case 2 the early diagnosis was possible due to the presence of pain and local signs of inflammation, plus a high clinical suspicion. Although in this later case the host and virulence factors also favored the development of a severe OM, the timely recognition and early and correct intervention resulted in a successful outcome.

These 2 cases most likely correspond to an acute and chronic presentation of hematogenous OM, respectively. In Case 1 there were symptoms of an inflammatory response, without localizing signs of infection, and concomitant CPKp bacteremia; but in Case 2 there was a history of CPKp bacteremia, which resolved, followed by appearance of a local inflammation with radiological signs suggestive of chronic inflammation \[[@b16-amjcaserep-20-482]\], and isolation of CPKp resistant to amikacin. In this particular case, we hypothesize that the patient remained colonized with CPKp in the femur, and relapsed after neutrophil recovery, with the formation of an abscess.

Although acute hematogenous OM might respond favorably to a 4- to 6-week course of IV antibiotics alone, in this case the treatment was compromised by the emergence of wide antibiotic resistance. In the chronic form, antibacterial therapy alone without adequate surgical debridement may be unsuccessful, regardless of the duration of therapy, due to the limited bone penetration of many antibiotics. Thus, surgical debridement is recommended in chronic OM \[[@b1-amjcaserep-20-482]\].

As described in Case 1, the symptoms and the clinical manifestations of OM may be nonspecific and mimic other infectious conditions; therefore, a high index of suspicion is required for early diagnosis. This raises the question of whether OM is underdiagnosed, particularly among neutropenic patients with a microbiologically confirmed infection and no identified primary infection locus.

Conclusions
===========

CPKp OM is an important diagnostic and therapeutic challenge, as illustrated by these 2 cases. Although rare, OM by CPKp should always be considered as a possible diagnosis, particularly among hospitalized patients with hematologic malignancies and stem cell transplant recipients, and a concomitant or previous infection by CPKp. Early recognition followed by an appropriate and aggressive treatment approach can improve the outcome of this severe and life-threatening condition.
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![**Pelvic computed tomography.** Images in bone window show coronal (**A**) and axial (**B**) cuts from right femoral neck and head. The different cuts show intramedullary gas bubbles characteristic of osteomyelitis.](amjcaserep-20-482-g001){#f1-amjcaserep-20-482}

![**Computed tomografy and magnetic resonance imaging of both thighs.** Coronal (**A**) and axial (**B**) CT images (bone window) of the right thigh, show a deep longitudinal collection adjacent to the femur which is connected to a subcutaneous collection, measuring 5.6 cm in diameter, through a cloaca in the femoral metaphyseal region. T1-weighted MRI image (**C**) shows an axial cut of both thighs. On the right thigh there is an intramedullary lesion consistent with an intraosseous abscess.](amjcaserep-20-482-g002){#f2-amjcaserep-20-482}

###### 

List of isolated *Klebsiella pneumonia* (Kp) over time and corresponding minimal inhibitory concentrations (MIC) of selected antimicrobial agents in Case 1.

  **(Case 1)**                                   **Date (day/month/year)**     **27-Jun-17**                                              **29-Jun-17**   **2-Jul-17**        **9-Jul-17**                                   **12-Jul-17**
  ---------------------------------------------- ----------------------------- ---------------------------------------------------------- --------------- ------------------- ---------------------------------------------- ---------------
  AST of culture isolates (with available MIC)   Carbapenamase                 **P**                                                      **P**           **P**               **P**                                          **P**
  Meropenem                                      **S (MIC 2 mcg/mL)**          R                                                          R               R (MIC 32 mcg/mL)   R                                              
  Imipenem                                       **S (MIC 2 mcg/mL)**          NA                                                         NA              R (MIC 16 mcg/mL)   R                                              
  Ertapenem                                      R                             NA                                                         NA              R                   R                                              
  Ampicillin                                     R                             R                                                          R               R                   R                                              
  Cefuroxime                                     R                             R                                                          R               R                   R                                              
  Cefotaxime                                     R                             R                                                          R               R                   R                                              
  Ceftazidime                                    R                             R                                                          NA              NA                  R                                              
  Amoxicillin-Clavulanic acid                    R                             R                                                          R               R                   R                                              
  Piperacillin-Tazobactam                        R                             NA                                                         R               R                   R                                              
  Trimethoprim/Sulfamethoxazole                  R                             R                                                          R               R                   R                                              
  Ciprofloxacin                                  R                             R                                                          R               R                   R                                              
  Fosfomycin                                     R                             NA                                                         NA              NA                  R                                              
  Amikacin                                       **S (MIC 4 mcg/mL)**          S                                                          **R**           R                   R                                              
  Gentamicin                                     R                             R                                                          R               R                   R                                              
  Colistin                                       S                             S                                                          S               S                   **R**                                          
  Tigecycline                                    NA                            NA                                                         NA              NA                  R                                              
  Aztreonam                                      NA                            NA                                                         NA              NA                  R                                              
                                                 Neutrophil count (×10^9^/L)   0                                                          0.86            19.1                5.37                                           4.35
  IV Antibiotic therapy                          Colistin                      Loading dose of 8MU, followed by maintenance of 4MU q12h   4MU q12h        5MU q12h                                                           
  Meropenem                                      1 gr q8h                      2 gr q8h                                                                                                                                      
  Amikacin                                       1 gr q24h                                                                                                                                                                   
  Tigecycline                                                                                                                                                                 200 mg loading dose, followed by 100 mg q12h   

Drug-resistance was defined as follows: *multidrug-resistant* are non-susceptible to at least 1 agent in ≥3 antimicrobial categories; *extensively drug-resistant* are non-susceptible to at least 1 agent in all but 2 or fewer antimicrobial categories; *pandrug-resistant* are non-susceptible to all agents in all antimicrobial categories \[[@b22-amjcaserep-20-482]\]. AST -- antimicrobial susceptibility testing; MIC -- minimum inhibitory concentration; S -- susceptible; R -- resistant; NA -- not available.

###### 

List of isolated *Klebsiella pneumonia* (Kp) over time and corresponding minimal inhibitory concentrations (MIC) of selected antimicrobial agents in Case 2.

  **(Case 2)**                                   **Date (day/month/year)**     **1-Jul-16**                                               **24-Apr-17**                                              **22-Jun-17**
  ---------------------------------------------- ----------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------
  AST of culture isolates (with available MIC)   Carbapenamase                 **P**                                                      **P**                                                      **P**
  Meropenem                                      R (MIC 16 mcg/mL)             R (MIC \>16 mcg/mL)                                        R (MIC \>16 mcg/mL)                                        
  Imipenem                                       R (MIC 8 mcg/mL)              R (MIC \>8 mcg/mL)                                         R (MIC \>16 mcg/mL)                                        
  Ertapenem                                      R                             NA                                                         R                                                          
  Ampicillin                                     R                             R                                                          R                                                          
  Cefuroxime                                     R                             R                                                          R                                                          
  Cefotaxime                                     R                             R                                                          R                                                          
  Ceftazidime                                    R                             R                                                          R                                                          
  Amoxicillin-Clavulanic acid                    R                             R                                                          R                                                          
  Piperacillin-Tazobactam                        R                             NA                                                         R                                                          
  Trimethoprim/Sulfamethoxazole                  R                             R                                                          R                                                          
  Ciprofloxacin                                  R                             R                                                          R                                                          
  Fosfomycin                                     NA                            S                                                          NA                                                         
  Amikacin                                       **S (6 mcg/mL)**              R (MIC 16 mcg/mL)                                          R (MIC 24 mcg/mL)                                          
  Gentamicin                                     R                             R                                                          R                                                          
  Colistin                                       S                             S                                                          S                                                          
  Tigecycline                                    S                             S                                                          S                                                          
                                                 Neutrophil count (×10^9^/L)   1.1                                                        22.03                                                      3.54
  IV Antibiotic                                  Colistin                      Loading dose of 8MU, followed by maintenance of 4MU q12h   Loading dose of 8MU, followed by maintenance of 4MU q12h   4MU q12h
  Amikacin                                       1 gr q24h                                                                                                                                           
  Tigecycline                                                                  200 mg loading dose, followed 100 mg q12h                  100 mg q12h                                                

Drug-resistance was defined as follows: *multidrug-resistant* are non-susceptible to at least 1 agent in ≥3 antimicrobial categories; *extensively drug-resistant* are non-susceptible to at least 1 agent in all but 2 or fewer antimicrobial categories; *pandrug-resistant* are non-susceptible to all agents in all antimicrobial categories \[[@b22-amjcaserep-20-482]\]. AST -- antimicrobial susceptibility testing; MIC -- minimum inhibitory concentration; S -- susceptible; R -- resistant; NA -- not available.
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